Aim: We conducted a prospective study in an Chinese population to detect associations of GSTM, GSTT andGSTP polymorphisms with hepatocellular carcinoma (HCC), and analyze roles in determining survival outcome.
Methods: A prospective follow-up study was conducted with 476 HCC patients and 481 controls collected fromMay 2005 to May 2007. All patients were followed up until the end of Dec. 2011. GSTM1, GSTT1 and GSTP1genotyping were performed by PCR-CTPP methods.
Results: Null GSTM1 carriers had a 1.64 fold risk of HCCcompared with non-null genotype, while GSTP1 Val/Val carriers had a 93% increased risk over the GSTP1IIe/IIe genotype. The median follow-up time for the 476 patients was 34.2 months (range: 1 to 78 months).Individuals with null GSTM1 genotype had better survival of HCC than non-null genotype carriers ( HR=0.71,95%CI=0.45-0.95). Similarly, GSTP1 Val/Val genotypes had significant better survival than the GSTP1 IIe/IIegenotype (HR=0.34, 95%CI=0.18-0.65). Individuals carrying null GSTM1 and GSTP1 Val/Val who receivedchemotherapy had lower risk of death from HCC than those without chemotherapy.
Conclusion: This studyindicated carriage of null GSTM1 and GSTP1 Val/Val genotypes to have roles in susceptibility to and survivalfrom HCC.